Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Antigens, Neoplasm/immunology"'
Publikováno v:
Journal of Leukocyte Biology
Journal of Leukocyte Biology, 2020, 108 (4), pp.1067-1079. ⟨10.1002/JLB.1MR0520-746R⟩
Journal of Leukocyte Biology, 2020, 108 (4), pp.1067-1079. ⟨10.1002/JLB.1MR0520-746R⟩
Innovative immunotherapies based on immune checkpoint targeting antibodies and engineered T cells are transforming the way we approach cancer treatment. However, although these T cell centered strategies result in marked and durable responses in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfc95014385f55a1f07ac5fb0e34df16
https://pubmed.ncbi.nlm.nih.gov/32620049
https://pubmed.ncbi.nlm.nih.gov/32620049
Autor:
Deschamps, Marina, Decot, Véronique, Giverne, Camille, Pinturaud, Marine, Vaissié, Alix, Parquet, Nathalie, Olivero, Sylvain, Mamez, Anne-Claire, Bay, Jacques-Olivier, Yakoub-Agha, Ibrahim, Ferrand, Christophe
Publikováno v:
Bulletin du cancer, Vol. 107, No 1S (2020) pp. S85-S93
The extraordinary and unexpected success of cellular immunotherapy using genetically engineered T-cells to express a chimeric antigen receptor (CAR) targeting CD19, in the treatment of refractory or relapsing B-hematological malignancies, has provide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1400::fc3930c51bdf3f23532771b56c7ef998
https://archive-ouverte.unige.ch/unige:154738
https://archive-ouverte.unige.ch/unige:154738
Autor:
Michal Bassani-Sternberg, Elise Ramia, Brian Stevenson, Greta Forlani, Elodie Lauret Marie Joseph, Michael Linnebacher, Roberto S. Accolla, Florian Huber, HuiSong Pak, Justine Michaux
Publikováno v:
Molecular & Cellular Proteomics : MCP
Molecular & cellular proteomics, vol. 20, pp. 100032
Molecular & cellular proteomics, vol. 20, pp. 100032
CD4+ T cell responses are crucial for inducing and maintaining effective anticancer immunity, and the identification of human leukocyte antigen class II (HLA-II) cancer-specific epitopes is key to the development of potent cancer immunotherapies. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfcddca7fc19ba47138689bfadc4b41e
http://hdl.handle.net/11383/2103085
http://hdl.handle.net/11383/2103085
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-17 (2019)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 284
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 284
Affinity-optimized T cell receptor (TCR)-engineered lymphocytes targeting tumor antigens can mediate potent antitumor responses in cancer patients, but also bear substantial risks for off-target toxicities. Most preclinical studies have focused on T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::224ac72dd3912a3ea58d339d6d2da6f6
https://doi.org/10.1186/s40425-019-0773-z
https://doi.org/10.1186/s40425-019-0773-z
Autor:
Marij J. P. Welters, Dominik Maurer, Ulrik Lassen, Martin Löwer, Bernhard Rossler, Ugur Sahin, Andreas von Deimling, Toni Weinschenk, Christian H. Ottensmeier, Elisa Rusch, Colette Song, Valérie Dutoit, Jordi Rodon, Norbert Hilf, Hans Skovgaard Poulsen, Nina Pawlowski, Francisco Martínez-Ricarte, Judith R. Kroep, Juan Sahuquillo, Claudia Wagner, Edward W. Green, Sonja Dorner, Cedrik M. Britten, Franziska Hoffgaard, Jens Fritsche, Ghazaleh Tabatabai, Stefan Stevanovic, Harpreet Singh-Jasuja, Marco Skardelly, Sabrina Kuttruff-Coqui, Hans-Georg Rammensee, Katharina Kiesel, Alexander Ulges, Carsten Reinhardt, Michael Platten, Alexandra Kemmer-Brück, Bracha Shraibman, Denis Migliorini, Sebastian Kreiter, Jordi Piro, Oliver Schoor, Valesca Bukur, Katrin Frenzel, Berta Ponsati, David Capper, Jorg Ludwig, Monika Stieglbauer, Regina Mendrzyk, Miriam Meyer, Sjoerd H. van der Burg, Evelyna Derhovanessian, Pierre-Yves Dietrich, Arie Admon, Arbel D. Tadmor, Manja Idorn, Wolfgang Wick, Hideho Okada, Per thor Straten, Sandra Heesch, Lukas Bunse, Christoph Huber, Katy J. McCann, Cécile Gouttefangeas, John C. Castle
Publikováno v:
Nature, 565(7738), 240
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b11cf9d2f3e8456103640b3a57a625
https://hdl.handle.net/1887/119498
https://hdl.handle.net/1887/119498
Autor:
Cinzia Solinas, John Stagg, Bertrand Allard, Christos Sotiriou, Laurence Buisseret, Soizic Garaud, Sandrine Aspeslagh, Bertrand Routy, Marleen Kok, Floriane Dupont
Cancer immunotherapy is demonstrating impressive clinical benefit in different malignancies and clinical oncologists are increasingly turning their attention to immune-oncology. It is now well recognized that innate and adaptive immune cells infiltra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3dc1fc9f46c7ac87db4c1e3e38daa2d
https://biblio.vub.ac.be/vubir/(38f19da3-c74f-4112-8f4d-2c903f3ed4fd).html
https://biblio.vub.ac.be/vubir/(38f19da3-c74f-4112-8f4d-2c903f3ed4fd).html
Autor:
Janos L. Tanyi, George Coukos, Brian Stevenson, Laurent Derré, Dimitri S. Monos, Alexandra Michel, Sara Bobisse, Vincent Zoete, Julien Racle, Olivier Michielin, Pedro Romero, Ioannis Xenarios, Christian Iseli, David Gfeller, Valentina Bianchi, Marie-Aude Le Bitoux, Raphael Genolet, Alexandre Harari, Craig Fenwick, Lana E. Kandalaft, Philippe Guillaume, Annalisa Roberti, Denarda Dangaj, Julien Schmidt
Publikováno v:
Nature communications, vol. 9, no. 1, pp. 1092
Nature Communications, Vol 9, Iss 1, Pp 1-10 (2018)
Nature Communications, Vol 9, Iss 1, Pp 1-10 (2018)
Immunotherapy directed against private tumor neo-antigens derived from non-synonymous somatic mutations is a promising strategy of personalized cancer immunotherapy. However, feasibility in low mutational load tumor types remains unknown. Comprehensi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1919f934ded5e32fd9ef810386741640
https://serval.unil.ch/notice/serval:BIB_10AE95ADCEE8
https://serval.unil.ch/notice/serval:BIB_10AE95ADCEE8
Publikováno v:
Ormhøj, M, Bedoya, F, Frigault, M J & Maus, M V 2017, ' CARs in the Lead Against Multiple Myeloma ', Current Hematologic Malignancy Reports, vol. 12, no. 2, pp. 119–125 . https://doi.org/10.1007/s11899-017-0373-2
The recent clinical success of CD19-directed chimeric antigen receptor (CAR) T cell therapy in chronic and acute leukemia has led to increased interest in broadening this technology to other hematological malignancies and solid tumors. Now, advances
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf1a83306afdaeda09a09fae0b7fbfaf
https://pubmed.ncbi.nlm.nih.gov/28233151
https://pubmed.ncbi.nlm.nih.gov/28233151
Autor:
ANTONIO JURETIĆ, MARTINA BAŠIĆ-KORETIĆ
Publikováno v:
Liječnički vjesnik
Volume 139
Issue 5-6
Volume 139
Issue 5-6
Nedavni uspješni rezultati više raznih novih imunoterapijskih pristupa u onkoloških bolesnika, kao, primjerice, blokada imunosnih inhibitornih molekularnih interakcija s monoklonskim protutijelima protiv molekula kontrolnih točaka, mogu se smatra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______951::2db81bb2967331325f20d06b98b9de18
https://hrcak.srce.hr/file/276146
https://hrcak.srce.hr/file/276146
Autor:
Matthias Kreuzaler, Min Lu, Stephanie Darbre, Alfred Zippelius, Daniel D. Pinschewer, Mario Kreutzfeldt, Philipp Müller, Nicolas Page, Weldy V. Bonilla, Stéphanie Favre, Sandra M. Kallert, Max Löhning, Sanjiv A. Luther, Doron Merkler, Florian Kreppel
Publikováno v:
Nature Communications, Vol. 8 (2017) P. 15327
Nature Communications
Nature communications, vol. 8, pp. 15327
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Nature Communications
Nature communications, vol. 8, pp. 15327
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Viral infections lead to alarmin release and elicit potent cytotoxic effector T lymphocyte (CTLeff) responses. Conversely, the induction of protective tumour-specific CTLeff and their recruitment into the tumour remain challenging tasks. Here we show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84cecd39857413817068e6b7d5865400
https://archive-ouverte.unige.ch/unige:98397
https://archive-ouverte.unige.ch/unige:98397